ESTRO 2022 | How could radiomics improve oncology care in the future?

Dirk De Ruysscher, MD, PhD, Maastricht University Medical Center, Maastricht, Netherlands, and University of Leuven, Leuven, Belgium, discusses the possible uses for radiomics in the future clinical practice of oncology, including identification of high- and low-risk patients, early detection of responses to treatments, differential diagnosis, and better molecular characterisation of tumors. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.